We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current REPL market cap is 866.42M. The company's latest EPS is USD -2.8020 and P/E is -4.39.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -56.54M | -58.76M | -57.37M | -58.92M | -66.02M |
| Net Income | -51.12M | -55.08M | -53.77M | -53.06M | -66.34M |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -56.2M | -79.96M | -118.31M | -177.08M | -234.77M |
| Net Income | -52.63M | -80.87M | -118.04M | -174.28M | -215.79M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 532.93M | 487.72M | 534.97M | 498.2M | 603.63M |
| Total Liabilities | 111.39M | 113.21M | 108.51M | 116.74M | 121.25M |
| Total Equity | 421.54M | 374.51M | 426.45M | 381.46M | 482.37M |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 234.1M | 543.1M | 461.19M | 646.59M | 487.72M |
| Total Liabilities | 50.38M | 44.37M | 49.96M | 91.3M | 113.21M |
| Total Equity | 183.72M | 498.73M | 411.23M | 555.29M | 374.51M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -139.3M | -185.47M | -49.17M | -87.81M | -138.52M |
| Investing | 74M | 97.2M | 29.77M | 30.22M | -16.1M |
| Financing | 16.41M | 16.28M | 96.64M | 96.6M | 252.53M |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -60.55M | -61.39M | -82.18M | -128.05M | -185.47M |
| Investing | -5.23M | -188.78M | -1.81M | -142.5M | 97.2M |
| Financing | 100.17M | 372.46M | 6.6M | 311.3M | 16.28M |
| Market Cap | 866.42M |
| Price to Earnings Ratio | -4.39 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 12.71 |
| Price to Book Ratio | 2.53 |
| Dividend Yield | - |
| Shares Outstanding | 77.01M |
| Average Volume (1 week) | 721.59k |
| Average Volume (1 Month) | 609.53k |
| 52 Week Change | 26.98% |
| 52 Week High | 16.52 |
| 52 Week Low | 4.92 |
| Spread (Intraday) | 5.79 (38.86%) |
| Company Name | Replimune Group Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.replimune.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
